TY - JOUR
T1 - Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients
AU - Miyoshi, Toru
AU - Doi, Masayuki
AU - Hirohata, Satoshi
AU - Kamikawa, Shigeshi
AU - Usui, Shinichi
AU - Ogawa, Hiroko
AU - Sakane, Kosuke
AU - Izumi, Reishi
AU - Ninomiya, Yoshifumi
AU - Kusachi, Shozo
N1 - Funding Information:
This work was supported in part by funding from a grant-in-aid for Scientific Research from the Japan Society for the Promotion of Science (20790531 to T.M.).
PY - 2011/7
Y1 - 2011/7
N2 - Adipocyte fatty acid binding protein (A-FABP) has been reported to be involved in insulin resistance, lipid metabolism, and atherosclerosis; however, little is known about the effect of medication on the change in circulating A-FABP in human subjects. We evaluated the effects of angiotensin II type 1 receptor blocker (ARB) on arterial stiffness and its association with serum A-FABP in patients with hypertension. Thirty patients newly diagnosed with essential hypertension were treated with olmesartan (20 mg/day), an ARB, for 6 months. Serum levels of A-FABP and high-sensitivity C-reactive protein (hsCRP) were examined and the cardio-ankle vascular index (CAVI), which is a marker of arterial stiffness, was also determined. Serum A-FABP at baseline was significantly correlated with the body mass index (r = 0.45, P = 0.01), homeostasis model assessment as a marker of insulin resistance (r = 0.53, p>0.01), and systolic blood pressure (r = 0.37, P = 0.047), and tended to be correlated with low-density lipoprotein cholesterol, triglyceride, and CAVI. Olmesartan treatment resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides a significant reduction of blood pressure. Multiple regression analysis revealed that the change in CAVI was independently correlated with the change in serum A-FABP. Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.
AB - Adipocyte fatty acid binding protein (A-FABP) has been reported to be involved in insulin resistance, lipid metabolism, and atherosclerosis; however, little is known about the effect of medication on the change in circulating A-FABP in human subjects. We evaluated the effects of angiotensin II type 1 receptor blocker (ARB) on arterial stiffness and its association with serum A-FABP in patients with hypertension. Thirty patients newly diagnosed with essential hypertension were treated with olmesartan (20 mg/day), an ARB, for 6 months. Serum levels of A-FABP and high-sensitivity C-reactive protein (hsCRP) were examined and the cardio-ankle vascular index (CAVI), which is a marker of arterial stiffness, was also determined. Serum A-FABP at baseline was significantly correlated with the body mass index (r = 0.45, P = 0.01), homeostasis model assessment as a marker of insulin resistance (r = 0.53, p>0.01), and systolic blood pressure (r = 0.37, P = 0.047), and tended to be correlated with low-density lipoprotein cholesterol, triglyceride, and CAVI. Olmesartan treatment resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides a significant reduction of blood pressure. Multiple regression analysis revealed that the change in CAVI was independently correlated with the change in serum A-FABP. Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.
KW - Adipocyte
KW - angiotensin II receptor antagonist
KW - atherosclerosis
KW - fatty acid
KW - hypertension
KW - inflammation
UR - http://www.scopus.com/inward/record.url?scp=80051471966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051471966&partnerID=8YFLogxK
U2 - 10.1007/s00380-010-0060-x
DO - 10.1007/s00380-010-0060-x
M3 - Article
C2 - 21063874
AN - SCOPUS:80051471966
VL - 26
SP - 408
EP - 413
JO - Heart and Vessels
JF - Heart and Vessels
SN - 0910-8327
IS - 4
ER -